Central Precocious Puberty: Revisiting The Diagnosis And Therapeutic Management

Clinical and laboratory diagnosis and treatment of central precocious puberty (CPP) remain challenging due to lack of standardization. The aim of this revision was to address the diagnostic and therapeutic features of CPP in Brazil based on relevant international literature and availability of the existing therapies in the country. The diagnosis of CPP is based mainly on clinical and biochemical parameters, and a period of follow-up is desirable to define the "progressive" form of sexual precocity. This occurs due to the broad spectrum of pubertal development, including isolated premature thelarche, constitutional growth and puberty acceleration, progressive and nonprogressive CPP, and early puberty. Measurement of basal and stimulated LH levels remains challenging, considering that the levels are not always in the pubertal range at baseline, short-acting GnRH is not readily available in Brazil, and the cutoff values differ according to the laboratory assay. When CPP is suspected but basal LH values are at prepubertal range, a stimulation test with short-acting or long-acting monthly GnRH is a diagnostic option. In Brazil, the treatment of choice for progressive CPP and early puberty is a long-acting GnRH analog (GnRHa) administered once a month or every 3 months. In Brazil, formulations of GnRHa (leuprorelin and triptorelin) are available and commonly administered, including 1-month depot leuprorelin 3.75 mg and 7.5 mg, 1-month depot triptorelin 3.75 mg, and 3-month depot leuprorelin 11.25 mg. Monthly or 3-month depot GnRHa are effective and safe to treat CPP.602163172Abbvi

Atualização em etiologia, diagnóstico e manejo da precocidade sexual

Precocious puberty is defined as the development of secondary sexual characteristics before the age of 8 years in girls and 9 years in boys. Gonadotropin-dependent precocious puberty (GDPP) results from the premature activation of the hypothalamic-pituitary-gonadal axis and mimics the physiological pubertal development, although at an inadequate chronological age. Hormonal evaluation, mainly through basal and GnRH-stimulated LH levels shows activation of the gonadotropic axis. Gonadotropin-independent precocious puberty (GIPP) is the result of the secretion of sex steroids, independently from the activation of the gonadotropic axis. Several genetic causes, including constitutive activating mutations in the human LH-receptor gene and activating mutations in the Gs protein a-subunit gene are described as the etiology of testotoxicosis and McCune-Albright syndrome, respectively. The differential diagnosis between GDPP and GIPP has direct implications on the therapeutic option. Long-acting gonadotropin-releasing hormone (GnRH) analogs are the treatment of choice in GDPP. The treatment monitoring is carried out by clinical examination, hormonal evaluation measurements and image studies. For treatment of GIPP, drugs that act by blocking the action of sex steroids on their specific receptors (cyproterone, tamoxifen) or through their synthesis (ketoconazole, medroxyprogesterone, aromatase inhibitors) are used. In addition, variants of the normal pubertal development include isolated forms of precocious thelarche, precocious pubarche and precocious menarche. Here, we provide an update on the etiology, diagnosis and management of sexual precocity.A puberdade precoce é definida como o desenvolvimento dos caracteres sexuais secundários antes dos 8 anos nas meninas e dos 9 anos nos meninos. A puberdade precoce dependente de gonadotrofinas (PPDG) resulta da ativação prematura do eixo hipotálamo-hipófise-gonadal e mimetiza o desenvolvimento puberal fisiológico, embora em idade cronológica inadequada. A avaliação hormonal, principalmente os valores de LH basal e após estímulo com GnRH exógeno confirmam a ativação do eixo gonadotrófico. A puberdade precoce independente de gonadotrofinas (PPIG) é o resultado da secreção de esteróides sexuais independentemente da ativação do eixo gonadotrófico. Diversas causas genéticas, incluindo mutações ativadoras constitutivas no gene do receptor do LH humano e mutações ativadoras no gene da subunidade a da proteína G representam as etiologias da testotoxicose e da síndrome de McCune Albright, respectivamente. O diagnóstico diferencial entre PPDG e PPIG tem implicação direta na opção terapêutica. Análogos de GnRH de ação prolongada é o tratamento de escolha da PPDG. A monitorização do tratamento da PPDG é realizada pelo exame clínico, avaliação hormonal e exames de imagem. Para o tratamento da PPIG, são usadas drogas que bloqueiam a ação dos esteróides sexuais nos seus receptores específicos (ciproterona, tamoxifeno) ou bloqueiam a sua síntese (cetoconazol, medroxiprogesterona e inibidores da aromatase). Variantes do desenvolvimento puberal normal incluem as formas isoladas de telarca, pubarca e menarca precoces. Nesta revisão, atualizamos a etiologia, o diagnóstico e tratamento da precocidade sexual.Universidade de São Paulo (USP) - Fundação Faculdade de Medicin

Mutation analysis of NANOS3 in Brazilian women with primary ovarian failure

OBJECTIVES: Primary ovarian failure is a rare disorder, and approximately 90% of cases are of unknown etiology. The aim of this study was to search for mutations in NANOS3, a gene that was recently related to the etiology of primary ovarian failure, in a group of Brazilian women. METHODS: We screened for NANOS3 DNA variants in 30 consecutive women who were previously diagnosed with primary ovarian failure, of unknown etiology and compared the results with those from 185 women with normal fertility. The NANOS3 gene was amplified by polymerase chain reaction using pairs of specific primers and then sequenced. The resulting sequences were compared with control sequences available in the National Center for Biotechnology and Information database. RESULTS: No mutations in NANOS3 were found in primary ovarian failure patients, but four previously described polymorphisms were identified at a similar frequency in the control and primary ovarian failure groups. CONCLUSIONS: Mutations in NANOS3 were not associated with primary ovarian failure in the present cohort

Sexuality and fertility desire in a large cohort of individuals with 46, XY differences in sex development

Objective: To analyze aspects of sexual life and fertility desire among 46, XY DSD people, including those who changed their gender. Methods: It is a cross-sectional study including 127 adults (> 16 years of age) with 46, XY DSD (83 females; 44 males) from a Single Brazilian Tertiary-Care Medical Center. Results: Sexual fantasies and masturbation were more frequent in 46, XY DSD males, whereas orgasm and sexual life satisfaction were similar in both genders. More 46, XY DSD men than women had a long-term romantic relationship. 46, XY DSD women with prenatal androgen exposure reported more fear of being romantically rejected. External genitalia appearance at birth did not impact the sexuality of 46, XY DSD women after surgical genital treatment had been completed. Overall, the sexual life was similar between 46, XY men assigned as males and those who changed to the male gender. Regarding sexual orientation, most self-reported as heterosexual (91% and 92% of women and men, respectively). The desire for fertility had a similar prevalence in both genders, but more women than men considered infertility a barrier to a long-term romantic relationship. Twelve individuals (7 males) had children; 10 out of 12 have adopted children. Conclusion: Fertility desire was shared among 46, XY DSD people, regardless of gender. Prenatal androgen exposure reduced the desire for motherhood in 46, XY women. 46, XY DSD people who changed from female to male gender presented similar sexual parameters as those assigned as males. Among females, virilized genitalia at birth did not affect sexuality once the surgical treatment is completed

Study of the gamma-aminobutyric acid type A receptor alpha-1 subunit gene (GABRA1) and electroencephalographic analysis in girls with gonadotropin-dependent precocious puberty

O ácido gama-aminobutírico (GABA), principal neurotransmissor inibitório, está envolvido no mecanismo intrínseco do início da puberdade. Os efeitos inibitórios do GABA sobre a secreção de GnRH (hormônio hipotalâmico estimulador da secreção das gonadotrofinas) são mediados pelo receptor tipo A (GABAA) que é composto por diferentes subunidades organizadas de forma heteropentamérica. A subunidade a1, codificada pelo gene GABRA1 localizado no locus 5q34-35, é a mais implicada na atividade inibitória do GABA. A puberdade precoce dependente de gonadotrofinas (PPDG) predomina no sexo feminino, sendo na maioria dos casos idiopática. Recentemente, defeitos moleculares das subunidades dos receptores de GABA têm sido identificados em pacientes com anormalidades eletroencefalográficas específicas. Neste estudo, investigamos a presença de mutações funcionais ou polimorfismos do GABRA1 em meninas com a forma idiopática de PPDG e avaliamos as anormalidades EEG neste grupo. Trinta e uma meninas com diagnóstico clínico e hormonal da forma idiopática da PPDG, sendo 6 casos familiais (19,4%) e 25 casos esporádicos (80,6%), e 73 controles não relacionados foram selecionados. Todas as pacientes com PPDG apresentaram ressonância magnética de sistema nervoso central normal. Vinte e três meninas foram submetidas a estudo eletroencefalográfico (EEG). O DNA genômico foi extraído do sangue periférico de todas as pacientes e controles. A região codificadora do GABRA1 foi amplificada utilizando-se oligonucleotídeos intrônicos específicos, seguida por purificação enzimática e seqüenciamento automático. Dois polimorfismos conhecidos do GABRA1 foram também estudados pelo programa GeneScan e pela técnica de digestão enzimática (enzima TaiI). O seqüenciamento automático do GABRA1 não revelou mutações funcionais. Identificamos 7 polimorfismos no GABRA1: duas variantes exônicas 156T>C e 1323G>A, localizados no éxons 4 e 11, respectivamente, e 5 polimorfismos intrônicos - IVS2-712(GT)n, no íntron 2, caracterizado por número variável de repetições GT; IVS3+12A>T, no íntron 3; IVS8+45T>G no íntron 8; IVS9+76T>G no íntron 9 e IVS10+15G>A, no íntron 10. Estes polimorfismos não alteram o uso do sítio de splice original. Não houve diferença estatisticamente significante entre a distribuição genotípica e a freqüência alélica dos 2 polimorfismos exônicos e do polimorfismo IVS2-712(GT) encontrados no grupo de pacientes e no grupo controle. O EEG revelou anormalidades em 6 de 23 meninas (4 sem epilepsia). A distribuição genotípica e a freqüência alélica dos polimorfismos do GABRA1 não difereriram significativamente entre as pacientes com PPDG sem e com anormalidades eletroencefalográficas. Nós concluímos que mutações funcionais ou polimorfismos no GABRA1 não estão envolvidos na etiologia da forma idiopática da PPDG e não estão associadas às anormalidades eletroencefalográficas encontradas. Adicionalmente, a presença de alterações eletroencefalográficas em pacientes com PPDG sem epilepsia sugere que a análise eletroencefalográfica deva ser incluída na investigação da PPDGThe gamma-aminobutyric acid (GABA), a dominant inhibitory neurotransmitter, is involved in the intrinsic mechanism of the onset of the puberty. Their inhibitory effects on the GnRH (hypothalamic gonadotropin release hormone) secretion are mediated by type A receptor (GABAA), composed by different subunits which are organized in a heteropentameric form. The alpha-1 subunit, encode by GABRA1 gene located at locus 5q34- 35, is the most implicated in the inhibitory activity of GABA. The gonadotropin-dependent precocious puberty (GDPP) is predominant in females, being idiopathic in the majority of the cases. Recently, molecular defects of the GABA receptor subunits have been identified in patients with specific electroencephalographic (EEG) abnormalities. In this study, we investigated the presence of functional mutations or polymorphisms of the GABRA1 in girls with the idiopathic form of the GDPP and evaluated EEG abnormalities in this group. Thirty-one girls with clinical and hormonal diagnosis of GDPP idiopathic form, being 6 familial cases (19.4%) and 25 sporadic cases (80.6%), and 73 unrelated controls were selected. All patients with GDPP had normal magnetic resonance of central nervous system. Twenty-three girls were submitted to electroencephalographic study. Genomic DNA was extracted from peripheral blood of all patients and controls. The entire coding region of the GABRA1 was amplified using specific intronic oligonucleotides, followed by enzymatic purification and automatic sequencing. Two known polymorphisms of the GABRA1 were also studied by GeneScan software and digestion with restriction endonuclease TaiI. The automatic sequencing of the GABRA1 did not reveal any functional mutations. We identified 7 polymorphisms in the GABRA1: two silent exonic variants 156T>C e 1323G>A, located at exons 4 e 11, respectively, e 5 polymorphisms - IVS2-712(GT)n, at intron 2, characterized by a variable number of repeat GT; IVS3+12A>T, at intron 3; IVS8+45T>G at intron 8; IVS9+76T>G at intron 9 and IVS10+15G>A, at íntron 10. These polymorphisms did not alter the use of original splicing site. No significant statistical difference of the genotypic distribution and allele frequency of the exonic polymorphisms (156T>C and 1323G>A) and IVS2-712(GT)n between unrelated patients and control group was obtained. Electroencephalographic tracings were abnormal in 6 of 23 girls (4 without epilepsy). No significant statistical difference of the genotype distribution and allele frequence were found between patients without and with EEG abnormalities. We conclude that functional mutations or polymorphisms in the GABRA1 are not involved in the etiology of idiopathic GDPP in this study, and they are not associated with electroencephalografic abnormalities. In addition, EEG abnormalities present in girls with GDPP without epilepsy, suggest that EEG analysis should be included in the investigation of the precocious puberty

Mutation analysis of NANOS3 in Brazilian women with primary ovarian failure

OBJECTIVES: Primary ovarian failure is a rare disorder, and approximately 90% of cases are of unknown etiology. The aim of this study was to search for mutations in NANOS3, a gene that was recently related to the etiology of primary ovarian failure, in a group of Brazilian women. METHODS: We screened for NANOS3 DNA variants in 30 consecutive women who were previously diagnosed with primary ovarian failure, of unknown etiology and compared the results with those from 185 women with normal fertility. The NANOS3 gene was amplified by polymerase chain reaction using pairs of specific primers and then sequenced. The resulting sequences were compared with control sequences available in the National Center for Biotechnology and Information database. RESULTS: No mutations in NANOS3 were found in primary ovarian failure patients, but four previously described polymorphisms were identified at a similar frequency in the control and primary ovarian failure groups. CONCLUSIONS: Mutations in NANOS3 were not associated with primary ovarian failure in the present cohort